CORE--Basic, Preclinical, and Clinical Support Core

CORE--基础、临床前和临床支持核心

• 批准号: 6963068
• 负责人: CAROL J WIKSTRAND
• 金额: $ 28.77万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-05-01 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6963068
• 关键词: antineoplastics; antitumor antibody; athymic mouse; biomedical facility; combination cancer therapy; disease /disorder model; dosage; drug screening /evaluation; glioma; hybrid antibody; immunoconjugates; laboratory rat; medulloblastoma; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; nonhuman therapy evaluation

Core 1 provides : 1) preclinical evaluation and analysis of drugs and monoclonal reagents requisite for eventual clinical trial, 2) continued development of new reagents directed against targets identified by gene mining approaches in separately funded grants, and establishment and characterization of genetically modified antibody reagents for clinical application; and 3) preparation of IND applications for all reagents generated in this SRC or in separately funded grants. Preclinical evaluation includes the performance of all requisite certification assays for all reagents (drug, MAb, chimeric MAb molecules, constructs and conjugates) generated in the SRC, and currently supports Phase I/II trials elaborated in Project 4. The developmental role of Core 1 is to generate new or modified reagents for clinical application as described in Aim 1. Three areas are being pursued: 1) chimerization, fragment engineering, and biochemical and genomic production of MAb conjugates/constructs; 2) evaluation of drugs and antibody conjugates in athymic rodent models (subcutaneous (sc), intracranial (ic), and intrathecal (ith); neoplastic meningitis); and 3) preclinical characterization and development of reagents generated in other funded grants for compartmental therapy. MAb engineering. In addition to the successful chimerization of the MAbs in Phase I/II trials (81C6 and derivatives), we now have available the requisite methodology for the generation of diabodies, minibodies, and CH2 domain-deleted F(ab')2 MAbs for improved penetration, blood clearance, and/or lack of glomerular trapping for both direct therapeutic application and elicitation of cell mediated reactivity. In vivo models for CNS neoplasia therapy. Central to development of reagents is the consistent preclinical evaluation of stability, localizing ability, and tumoristatic or tumoricidal effect in models mimicking human CNS disease. We constantly refine our large repertoire (sc, ic, ith) of available models in athymic rats with new disease models (ependymoma) and new administration routes; e.g. it and ic with convection enhanced delivery methods, for preclinical assessment of specificity, efficacy, and lack of toxicity. Most unique to this program is the leptomeningeal meningitis model in athymic rats which allows not only establishment of CNS tumors with subarachnoid spread, but the ith administration of therapeutic reagents. Development of glioma-targeting reagents generated in separately funded grants. MAb reagents vs GPNMB, MRP3, SSTR2A, and glioma-associated gangliosides 3'-isoLM1 and 3',6'-isoLD1, generated under separate funding, will undergo preclinical evaluation under the auspices of this core.

核心1提供：1)最终临床试验所需的药物和单克隆试剂的临床前评估和分析；2)在单独资助的资助下，继续开发针对基因挖掘方法确定的靶点的新试剂，并建立和表征用于临床应用的转基因抗体试剂；3)为SRC或单独资助的所有试剂准备IND申请。临床前评估包括SRC中生成的所有试剂（药物、单抗、嵌合单抗分子、构建物和偶联物）的所有必要认证分析的性能，目前支持项目4中阐述的I/II期试验。核心1的发展作用是产生新的或修饰的试剂用于临床应用，如Aim 1所述。目前正在研究三个领域：1)嵌合、片段工程和生物化学